34,128 Shares in Abeona Therapeutics Inc (NASDAQ:ABEO) Acquired by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. bought a new position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 34,128 shares of the biopharmaceutical company’s stock, valued at approximately $190,000. Balyasny Asset Management L.P. owned 0.08% of Abeona Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp lifted its position in shares of Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 11,478 shares during the last quarter. Oxford Asset Management LLP bought a new position in Abeona Therapeutics in the 4th quarter worth approximately $118,000. JPMorgan Chase & Co. increased its position in Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 28,606 shares during the period. Bank of America Corp DE lifted its holdings in shares of Abeona Therapeutics by 16.7% during the fourth quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company’s stock worth $1,473,000 after buying an additional 37,774 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at approximately $341,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Analysts Set New Price Targets

ABEO has been the topic of a number of research reports. Oppenheimer began coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price on the stock. Stifel Nicolaus dropped their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Friday. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, HC Wainwright lifted their target price on Abeona Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $18.50.

Insider Buying and Selling

In related news, CEO Vishwas Seshadri sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the transaction, the chief executive officer now owns 1,355,322 shares in the company, valued at $6,478,439.16. This trade represents a 1.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Alvino sold 8,000 shares of the business’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $5.68, for a total value of $45,440.00. Following the completion of the sale, the director now directly owns 92,435 shares in the company, valued at approximately $525,030.80. This represents a 7.97% decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.90% of the company’s stock.

Abeona Therapeutics Stock Up 5.4%

Shares of ABEO stock opened at $6.10 on Monday. Abeona Therapeutics Inc has a one year low of $3.93 and a one year high of $7.32. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock has a fifty day moving average price of $5.18 and a 200 day moving average price of $5.55. The stock has a market cap of $297.68 million, a P/E ratio of -2.27 and a beta of 1.68.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.11. Analysts predict that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.